Além do rastreamento de infecções oportunistas específicas, conforme detalhado aqui, o monitoramento regular das contagens de CD4 permite o diagnóstico precoce e o tratamento imediato de infecções oportunistas.[206]Clinical Info HIV.gov. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Sep 2022 [internet publication].
Tuberculose (TB)
Todas as pessoas que vivem com HIV devem ser testadas quanto a infecção latente por TB (ITBL), independentemente do risco de TB.[1]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2025 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
[207]World Health Organization. WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease. Mar 2021 [internet publication].
https://www.who.int/publications/i/item/9789240022676
[208]U.S. Preventive Services Task Force. Latent tuberculosis infection in adults: screening. May 2023 [internet publication].
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/latent-tuberculosis-infection-screening
Recomenda-se realizar testagem anual para infecção latente nas pessoas que vivem com HIV que estejam ou permaneçam em alto risco de exposição repetida ou constante a indivíduos com TB ativa.[1]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2025 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
Dados de cenários de baixa incidência de TB mostram que 12% das pessoas vivendo com HIV testaram positivo para ITBL, com maior probabilidade de resultados positivos entre aquelas originárias de países endêmicos de TB ou com exposição prévia à TB.[209]van Geuns D, Arts RJW, de Vries G, et al. Screening for tuberculosis infection and effectiveness of preventive treatment among people with HIV in low-incidence settings. AIDS. 2024 Feb 1;38(2):193-205.
https://journals.lww.com/aidsonline/fulltext/2024/02010/screening_for_tuberculosis_infection_and.9.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37991008?tool=bestpractice.com
As pessoas com testes diagnósticos negativos para ITBL, infecção por HIV avançada (contagem de CD4 <200 células/microlitro) e sem nenhuma indicação de início de tratamento empírico para ITBL, devem ser testadas novamente para ITBL quando iniciarem a terapia antirretroviral e atingirem uma contagem de CD4 de 200 células/microlitro ou mais.[1]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2025 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
Dados de países com baixa incidência de TB mostram que o tratamento preventivo para ITBL reduziu a incidência de TB, com 20 indivíduos precisando de tratamento preventivo para evitar um caso de TB ativa.[209]van Geuns D, Arts RJW, de Vries G, et al. Screening for tuberculosis infection and effectiveness of preventive treatment among people with HIV in low-incidence settings. AIDS. 2024 Feb 1;38(2):193-205.
https://journals.lww.com/aidsonline/fulltext/2024/02010/screening_for_tuberculosis_infection_and.9.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37991008?tool=bestpractice.com
Toxoplasmose
Todas as pessoas que vivem com HIV devem ser testadas quanto a exposição pregressa ao Toxoplasma gondii por meio da dosagem de imunoglobulina G (IgG) antitoxoplasma ao início do tratamento.[1]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2025 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
Se os resultados forem positivos, deve-se fornecer profilaxia primária quando a contagem de CD4 estiver abaixo de 100 células/microlitro.[1]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2025 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
Se os resultados forem negativos, o indivíduo deverá ser aconselhado a evitar a infecção (evitar ingestão de carne malcozida e contato com fezes de gato).[1]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2025 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
Criptococose
Testes de rotina para o antígeno criptocócico sérico em pessoas recém-diagnosticadas com HIV e sem sinais clínicos aparentes de meningite podem ser considerados para indivíduos cuja contagem de CD4 seja ≤100 células/microlitros e, particularmente, em pessoas com contagens de CD4 ≤50 células/microlitros. Se positivo, o exame deve suscitar avaliação do líquido cefalorraquidiano para meningite.[1]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. 2025 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
[76]World Health Organization. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Jun 2022 [internet publication].
https://www.who.int/publications/i/item/9789240052178
Coccidioidomicose
Os indivíduos assintomáticos que residem em áreas onde a coccidioidomicose é endêmica e que apresentam uma contagem de CD4 ≤250 células/microlitro devem fazer um rastreamento sorológico anual de IgM e IgG para espécies de Coccidioides.[210]Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016 Sep 15;63(6):e112-46.
https://academic.oup.com/cid/article/63/6/e112/2389093
http://www.ncbi.nlm.nih.gov/pubmed/27470238?tool=bestpractice.com